
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1592118
This article is a correction to:
Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Corrigendum on: figure 3 of the article. In the published article, there was an error in Figure 3 as published. In the figure 3C, the figure of the non-permeabilized AdHu5-PfCSP is exactly similar with that of non-permeabilized AAV1-PfCSP-G(+). The corrected Figure 3 and its caption **Fig 3. Functional activity of AAV1-PfCSP-G(+). (A) Constructs of AAV1-PfCSP-G(+) and AdHu5-PfCSP-G(+). Expression of the pcsp gene cassette in AAV1 and AdHu5 was driven by a CMV promoter and CAG promoter, respectively. G, VSV-G. (B) Expression of PfCSP in HEK293T cells transduced with AdHu5-PfCSP (lane 1, MOI = 3), AAV1-PfCSP-G(–) (lane 2, MOI = 105 ), or AAV1-PfCSP-G(+) (lane 3, MOI = 105 ), as assessed by immunoblotting with mAb 2A10 at 48 h post-transduction. (C) Localization of PfCSP expression in HEK293T cells transduced with AAV1-PfCSP-G(+) (MOI = 105) and AdHu5-PfCSP (MOI = 10), as determined by IFA conducted as described in Figure 2C. (D) Anti-PfCSP IgG antibody responses. Groups of BALB/c mice (n = 10) were immunized with the indicated regimen at a 6-week interval. At 4 weeks post-boost, serum samples were collected from each mouse, and their anti-PfCSP IgG titers were determined by ELISA. AdHu5-PfCSP, AAV1-PfCSP-G(–), and AAV1-PfCSP (G+) are shown as AdHu5, AAV1-G(–), and AAV1-G(+), respectively. Bars and error bars indicate the means and SD of the values, respectively. Between-group differences were assessed with a Mann–Whitney U-test (*p < 0.05). appear below.
Keywords: Plasmodium falciparum circumsporozoite protein, Pfs25, human adenovirus serotype 5, adenoassociated virus, Malaria vaccine, transmission-blocking
Received: 12 Mar 2025; Accepted: 01 Apr 2025.
Copyright: © 2025 Yusuf, Yoshii, Iyori, Yoshida, Mizukami, Fukumoto, Alam, Emran, Amelia, Islam, Otsuka, Takashima, Tsuboi and Yoshida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shigeto Yoshida, Kanazawa University, Kanazawa, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.